Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367247 · ClinicalTrials.gov registry record · NA
BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 121
- Enrollment target
NCT03367247: Completed NA study, sponsored by Dana-Farber Cancer Institute.
NCT03367247 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 121 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03367247, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 121 participants
- Enrollment target
Study Summary
This research study is evaluating a new intervention, BOLSTER, which was designed to provide more support for patients with gynecologic and gastrointestinal cancers and their caregivers after a hospitalization.
Primary Outcome
≥50% consent-to-approach ratio
Interventions
- BEHAVIORAL BOLSTER
- OTHER Enhanced Discharge Planning (EDP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2018-04-24 |
| Est. Completion | 2023-07-27 |
| Phase | NA |
What the finished NCT03367247 record still lists
NCT03367247 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which BOLSTER is the first listed.
NCT03367247 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03367247 about?
NCT03367247 is a clinical study titled "BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal". This research study is evaluating a new intervention, BOLSTER, which was designed to provide more support for patients with gynecologic and gastrointestinal cancers and their caregivers after a hospitalization.
What is the current status of trial NCT03367247?
This trial is currently completed. It is a NA study. The enrollment target is 121 participants. The study started on 2018-04-24. Estimated completion is 2023-07-27.
What interventions are being tested in trial NCT03367247?
The interventions under investigation include: BOLSTER (BEHAVIORAL), Enhanced Discharge Planning (EDP) (OTHER).
Who is sponsoring clinical trial NCT03367247?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03367247's enrollment target sits among peer trials
121 762nd of 2000 higher than 1,239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI